Feinstein Institutes Expands Vagus Nerve Stimulation Trial for Lupus Patients

  • Feinstein Institutes' clinical trial for lupus patients using non-invasive vagus nerve stimulation (VNS) is now 50% enrolled.
  • The study evaluates pain and fatigue reduction over 28 days of daily stimulation, with an additional 28-day monitoring period.
  • Supported by a $450,000 grant from the Lupus Research Alliance over two years.
  • Builds on previous successful trial showing VNS efficacy in reducing lupus symptoms.
  • Part of Northwell Health’s Center for Bioelectronic Medicine, which explores VNS for multiple autoimmune and inflammatory diseases.

The trial underscores the growing momentum in bioelectronic medicine, a field that leverages the gut-brain axis to treat chronic diseases with fewer side effects than traditional pharmaceuticals. Feinstein Institutes' leadership in this space positions it at the forefront of a potential paradigm shift in autoimmune disease treatment. The $450,000 grant from the Lupus Research Alliance highlights the financial backing behind this innovative approach.

Trial Outcomes
Whether the trial confirms lasting effects of VNS on lupus symptoms beyond the initial 28-day stimulation period.
Regulatory Pathway
The pace at which bioelectronic medicine therapies gain FDA approval following the 2025 approval for rheumatoid arthritis.
Market Expansion
How Feinstein Institutes scales VNS applications across other autoimmune and inflammatory conditions.